WuXi Biologics (Cayman) Management

Management Kriterienprüfungen 2/4

WuXi Biologics (Cayman) CEO ist Chris Chen , ernannt in Jan 2016, hat eine Amtszeit von 8.83 Jahren. Die jährliche Gesamtvergütung beträgt CN¥96.91M , bestehend aus 4.1% Gehalt und 95.9% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.35% der Aktien des Unternehmens, im Wert von $26.80M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 2.6 Jahre bzw. 7.2 Jahre.

Wichtige Informationen

Chris Chen

Geschäftsführender

CN¥96.9m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	4.1%
Amtszeit als Geschäftsführer	8.8yrs
Eigentum des Geschäftsführers	0.4%
Durchschnittliche Amtszeit des Managements	2.6yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	7.2yrs

Jüngste Management Updates

Recent updates

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Chris Chen im Vergleich zu den Einnahmen von WuXi Biologics (Cayman) verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Jun 30 2024	n/a	n/a	CN¥3b
Mar 31 2024	n/a	n/a	CN¥3b
Dec 31 2023	CN¥97m	CN¥4m	CN¥3b
Sep 30 2023	n/a	n/a	CN¥4b
Jun 30 2023	n/a	n/a	CN¥4b
Mar 31 2023	n/a	n/a	CN¥4b
Dec 31 2022	CN¥79m	CN¥3m	CN¥4b
Sep 30 2022	n/a	n/a	CN¥4b
Jun 30 2022	n/a	n/a	CN¥4b
Mar 31 2022	n/a	n/a	CN¥4b
Dec 31 2021	CN¥51m	CN¥3m	CN¥3b
Sep 30 2021	n/a	n/a	CN¥3b
Jun 30 2021	n/a	n/a	CN¥3b
Mar 31 2021	n/a	n/a	CN¥2b
Dec 31 2020	CN¥31m	CN¥3m	CN¥2b
Sep 30 2020	n/a	n/a	CN¥1b
Jun 30 2020	n/a	n/a	CN¥1b
Mar 31 2020	n/a	n/a	CN¥1b
Dec 31 2019	CN¥25m	CN¥3m	CN¥1b
Sep 30 2019	n/a	n/a	CN¥922m
Jun 30 2019	n/a	n/a	CN¥831m
Mar 31 2019	n/a	n/a	CN¥731m
Dec 31 2018	CN¥20m	CN¥2m	CN¥631m
Sep 30 2018	n/a	n/a	CN¥520m
Jun 30 2018	n/a	n/a	CN¥410m
Mar 31 2018	n/a	n/a	CN¥331m
Dec 31 2017	CN¥24m	CN¥2m	CN¥253m

Vergütung im Vergleich zum Markt: ChrisDie Gesamtvergütung ($USD13.38M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt US ($USD7.78M).

Entschädigung vs. Einkommen: ChrisDie Bezüge der Mitarbeiter sind um mehr als 20 % gestiegen, während die Unternehmensgewinne im vergangenen Jahr um mehr als 20 % gesunken sind.

Geschäftsführer

Chris Chen (51 yo)

8.8yrs

Amtszeit

CN¥96,911,000

Vergütung

Dr. Zhisheng Chen, also known as Chris, Ph.D. has been the Chief Executive Officer & Executive Director at WuXi Biologics (Cayman) Inc. since January 01, 2016 and since February 27, 2014 respectively. Dr....

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Ge Li	Founder & Chairman	10.8yrs	keine Daten	keine Daten
Zhisheng Chen	CEO & Executive Director	8.8yrs	CN¥96.91m	0.35% $ 26.8m
Weichang Zhou	Honorary President of Global Biologics Development	9.6yrs	CN¥32.89m	0.013% $ 1.0m
Ming Tu	CFO & Executive VP	3yrs	keine Daten	keine Daten
Lihua Yu	COO & Senior VP	less than a year	keine Daten	keine Daten
Sherry Gu	Chief Technology Officer and Executive VP of Global Biologics Development Department	less than a year	keine Daten	keine Daten
Jijie Gu	Chief Scientific Officer & President of Global Biologics Research	no data	keine Daten	keine Daten
Lina Fan	Senior VP & Head of Investor Relations	less than a year	keine Daten	keine Daten
He Wang	Chief Compliance Officer	2.2yrs	keine Daten	keine Daten
Li Xiong	VP & Head of Global Human Resources	no data	keine Daten	keine Daten
Angus Scott Turner	Senior VP and Head of Global BD & Alliance Management	no data	keine Daten	keine Daten
Keqiang Shen	Chief Digital Officer	4.8yrs	keine Daten	keine Daten

2.6yrs

Durchschnittliche Betriebszugehörigkeit

56.5yo

Durchschnittliches Alter

Erfahrenes Management: WXIB.FDas Führungsteam des Unternehmens gilt als erfahren (2.6 Jahre durchschnittliche Betriebszugehörigkeit).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Ge Li	Founder & Chairman	10.8yrs	keine Daten	keine Daten
Zhisheng Chen	CEO & Executive Director	10.8yrs	CN¥96.91m	0.35% $ 26.8m
Weichang Zhou	Honorary President of Global Biologics Development	8.5yrs	CN¥32.89m	0.013% $ 1.0m
Jackson Tai	Independent Non-Executive Director	1.5yrs	CN¥710.00k	0.00063% $ 47.8k
James Larrick	Member of Scientific Advisory Board	6.8yrs	keine Daten	keine Daten
David D. Ho	Member of Scientific Advisory Board	6.8yrs	keine Daten	keine Daten
Wei-Shou Hu	Member of Scientific Advisory Board	6.8yrs	keine Daten	keine Daten
Ram Sasisekharan	Member of Scientific Advisory Board	6.8yrs	keine Daten	keine Daten
William Robert Keller	Independent Non-Executive Director	7.5yrs	CN¥906.00k	0.00053% $ 40.2k
Yanling Cao	Non-Executive Director	8.5yrs	keine Daten	keine Daten
Yibing Wu	Non-Executive Director	8.5yrs	keine Daten	keine Daten
Kenneth Walton Hitchner	Independent Non-Executive Director	4.4yrs	CN¥933.00k	0.0050% $ 375.9k

7.2yrs

Durchschnittliche Betriebszugehörigkeit

59.5yo

Durchschnittliches Alter

Erfahrener Vorstand: WXIB.FDie Vorstandsmitglieder gelten als erfahren (7.2 Jahre durchschnittliche Amtszeit).

WuXi Biologics (Cayman) Management

Management Kriterienprüfungen 2/4

Wichtige Informationen

Jüngste Management Updates

WuXi Biologics (Cayman) Inc., Annual General Meeting, Jun 19, 2024

WuXi Biologics (Cayman) Inc. Announces Executive Changes, Effective March 31, 2024

Wuxi Biologics (Cayman) Inc. Announces Executive Changes

WuXi Biologics (Cayman) Inc., Annual General Meeting, Jun 15, 2023

WuXi Biologics (Cayman) Inc. Announces Demise of Ning Zhao, Non-Executive Director, Member of Remuneration Committee and Member of Environmental, Social and Governance Committee

Recent updates

WuXi Biologics (Cayman) Inc. (SEHK:2269) completed the acquisition of remaining 30% stake in WuXi Vaccines (Cayman) Inc. from Shanghai Hile Bio-Technology Co., Ltd. (SHSE:603718).

WuXi Reportedly Explores Sale of Pharma Units as US Restrictions Loom

WuXi Biologics Successfully Completes First Scale-Up of High-Productivity Bioprocessing Platform WuXiUI in 2,000L GMP Manufacturing

WuXi Biologics (Cayman) Inc. to Report First Half, 2024 Results on Aug 21, 2024

WuXi Biologics (Cayman) Inc., Annual General Meeting, Jun 19, 2024

WuXi Biologics (Cayman) Inc.(SEHK:2269) dropped from S&P International 700

WuXi Biologics (Cayman) Inc. to Report Q4, 2023 Results on Mar 26, 2024

WuXi Biologics Successfully Completes First 1,6000L Manufacturing Run in Ireland

WuXi Biologics Launches WuXia ADCC PLUS™ for the Development and Manufacturing of Afucosylated Antibodies that Elicit Enhanced ADCC Effect

WuXi Biologics Receives U.S. Patent for Proprietary Bispecific Antibody Technology Platform WuXiBody™

WuXi Biologics (Cayman) Inc. Announces Executive Changes, Effective March 31, 2024

WuXi Biologics (Cayman) Inc. (SEHK:2269) commences an Equity Buyback Plan for 424,841,177 shares, representing 10% of its issued share capital, under the authorization approved on June 27, 2023.

Wuxi Biologics Successfully Implements Fully Integrated Continuous Process with Breakthrough Productivity of 6 g/L/Day At Pilot Scale

WuXi Biologics Launches New High-Productivity Bioprocessing Platform WuXiUI™ for Cost-Effective Commercial Manufacturing and Desirable Product Quality

Wuxi Biologics (Cayman) Inc. Announces Executive Changes

WuXi Biologics (Cayman) Inc. to Report First Half, 2023 Results on Aug 23, 2023

WuXi Biologics (Cayman) Inc., Annual General Meeting, Jun 15, 2023

WuXi Biologics (Cayman) Inc. Announces Demise of Ning Zhao, Non-Executive Director, Member of Remuneration Committee and Member of Environmental, Social and Governance Committee

WuXi Biologics (Cayman) Inc. Announces Board and Board Committee Changes

WuXi Biologics (Cayman) Inc. to Report Fiscal Year 2022 Results on Mar 22, 2023

WuXi Biologics (Cayman) Inc. Announces Demise of Teh-Ming Walter Kwauk, Independent Non-Executive Director, the Chairman of the Audit Committee of the Company and A Member of the Nomination Committee of the Company

Wuxi Biologics (Cayman) Inc. Announces Appointments to Strategy Committee

WuXi Biologics (Cayman) Inc. (SEHK:2269) commences an Equity Buyback Plan for 425,926,547 shares, representing 10% of its issued share capital, under the authorization approved on June 10, 2022.

WuXi Biologics (Cayman) Inc. Receives Regulatory Approvals for Drug Substance and Drug Product Facilities from U.S. FDA and EMA

WuXi Biologics (Cayman) Inc. Appoints Weichang Zhou as Member of the Strategy Committee

WuXi Biologics (Cayman) Inc. Provides Earnings Guidance for the Six Months Ended June 30, 2022

Wuxi Biologics (Cayman) Inc. Provides Unaudited Consolidated Earnings Guidance for the Ended December 31, 2021

WuXi Biologics Announces Completion of GMP Production At 24,000L Line of Its Drug Substance Facility MFG5

WuXi Biologics (Cayman) Inc. Provides Unaudited Consolidated Earnings Guidance for the Six Months Ended June 30, 2021

WuXi Biologics (Cayman) Inc. (SEHK:2269) completed the acquisition of Biologics manufacturing facilities in Hangzhou of Pfizer Investment Co. Ltd.

WuXi Biologics (Cayman) Inc. (SEHK:2269) agreed to acquire a 90% stake in CMAB Biopharma Inc. from CBC Group.

WuXi Biologics (Cayman) Inc. (SEHK:2269) entered into an equity agreement to acquire Biologics manufacturing facilities in Hangzhou of Pfizer Investment Co. Ltd.

Exelixis, Inc. Enters into License Agreement with WuXi Biologics to Support Further Expansion of its Growing Oncology Biologics Pipeline

Wuxi Biologics (Cayman) Inc. Receives Remote Pre-Approval Inspection by European Medicines Agency on MFG4 Facility

WuXi Biologics (Cayman) Inc. to Report Fiscal Year 2020 Results on Mar 23, 2021

Antengene Corporation Limited Announces Collaboration with WuXi Biologics and WuXi STA to Advance Antibody-Drug Conjugate Candidate into Clinical-stage

Oxford BioTherapeutics Ltd Designates Second Bispecific Antibody Program Leveraging Wuxi Biologics’ Wuxibody® Platform

Oxford BioTherapeutics Designates Second Bispecific Antibody Program Leveraging WuXi Biologics’ WuXiBody® Platform

WuXi Biologics Receives GMP Certification from Brazil's ANVISA

WuXi Biologics (Cayman) Inc. (SEHK:2269) agreed into an Asset Purchase Agreement to acquire Drug Substance Facility in Wuppertal from Bayer Aktiengesellschaft (XTRA:BAYN) for € 110 million.

Arcus Biosciences, Inc. Expands Strategic Relationship with WuXi Biologics to Develop a Best-in-Class anti-CD39 Antibody for the Treatment of Cancer

AC Immune and WuXi Biologics Strengthen Strategic Partnership to Accelerate AC Immune’s Anti-TDP-43 Antibodies into Clinical Development

WuXi Biologics and AB2 Bio Ltd. Announces Collaboration to Accelerate Commercial-Scale Manufacturing of Tadekinig alfa

Antengene Announces Collaboration with WuXi Biologics to Advance the Development of Innovative Oncology Medicines

WuXi Biologics (Cayman) Inc. has completed a Follow-on Equity Offering in the amount of HKD 6.165 billion.

Analyse der Geschäftsführervergütung

Geschäftsführer

Amtszeit

Vergütung

Führungsteam

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter

Vorstandsmitglieder

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter